主页 > 医学前沿 >
【文摘发布】《JCO》ASCO指南：对癌症患者静脉血
Purpose: To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer.
Methods: A comprehensive systematic review of the medical literature on the prevention and treatment of VTE in cancer patients was conducted and reviewed by a panel of content and methodology experts. Following discussion of the results, the panel drafted recommendations for the use of anticoagulation in patients with malignant disease.
Results: The results of randomized controlled trials of primary and secondary VTE medical prophylaxis, surgical prophylaxis, VTE treatment, and the impact of anticoagulation on survival of patients with cancer were reviewed. Recommendations were developed on the prevention of VTE in hospitalized, ambulatory, and surgical cancer patients as well as patients with established VTE, and for use of anticoagulants in cancer patients without VTE to improve survival.
Conclusion: Recommendations of the American Society of Clinical Oncology VTE Guideline Panel include (1) all hospitalized cancer patients should be considered for VTE prophylaxis with anticoagulants in the absence of bleeding or other contraindications; (2) routine prophylaxis of ambulatory cancer patients with anticoagulation is not recommended, with the exception of patients receiving thalidomide or lenalidomide; (3) patients undergoing major surgery for malignant disease should be considered for pharmacologic thromboprophylaxis; (4) low molecular weight heparin represents the preferred agent for both the initial and continuing treatment of cancer patients with established VTE; and (5) the impact of anticoagulants on cancer patient survival requires additional study and cannot be recommended at present.
http://jco.ascopubs.org/cgi/content/abstract/25/34/5490 没人认领啊？ 没人认领，我自己来试试吧！
本人认领此文编译，如在48小时内未能提交译文，其他战友自由认领。 American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
ASCO指南：对癌症患者静脉血栓形成(VTE)的预防和治疗推荐
Purpose: To develop guideline recommendations for the use of anticoagulation in the prevention and treatment of venous thromboembolism (VTE) in patients with cancer.
目的：为发展抗凝药物在癌症患者静脉血栓形成的预防和治疗推荐。
Methods: A comprehensive systematic review of the medical literature on the prevention and treatment of VTE in cancer patients was conducted and reviewed by a panel of content and methodology experts. Following discussion of the results, the panel drafted recommendations for the use of anticoagulation in patients with malignant disease.
方法：开展一项癌症患者VTE的预防和治疗医学文献的综合性的系统回顾并又内容和方法论的专家组来评价。根据对结果的讨论，专家组起草了关于恶性疾病患者抗凝药物的使用推荐。
Results: The results of randomized controlled trials of primary and secondary VTE medical prophylaxis, surgical prophylaxis, VTE treatment, and the impact of anticoagulation on survival of patients with cancer were reviewed. Recommendations were developed on the prevention of VTE in hospitalized, ambulatory, and surgical cancer patients as well as patients with established VTE, and for use of anticoagulants in cancer patients without VTE to improve survival.
结果：专家们回顾了关于原发和继发的VTE医学预防、外科预防，VTE治疗和癌症患者抗凝治疗对生存影响的随机对照试验的结果。因为未伴有VTE的癌症患者中抗凝剂的使用提高了患者的存活，故专家们对于住院，卧床和手术未伴有VTE的癌症患者的VTE预防起草了其推荐。
Conclusion: Recommendations of the American Society of Clinical Oncology VTE Guideline Panel include (1) all hospitalized cancer patients should be considered for VTE prophylaxis with anticoagulants in the absence of bleeding or other contraindications; (2) routine prophylaxis of ambulatory cancer patients with anticoagulation is not recommended, with the exception of patients receiving thalidomide or lenalidomide; (3) patients undergoing major surgery for malignant disease should be considered for pharmacologic thromboprophylaxis; (4) low molecular weight heparin represents the preferred agent for both the initial and continuing treatment of cancer patients with established VTE; and (5) the impact of anticoagulants on cancer patient survival requires additional study and cannot be recommended at present.
结论： VTE的ASCO指南小组的推荐包括：（1）所有住院癌症患者在没有出血或别的禁忌症的情况下，应该使用抗凝剂进行VTE预防；（2）卧床癌症患者不推荐常规给予抗凝剂预防，但接受了thalidomide 或 lenalidomide的患者除外；（3）恶性疾病且经历大手术的患者应该考虑药物抗凝；（4）低分子肝素是癌症患者出现VTE起始和持续治疗的首选代表药物；（5）抗凝剂对癌症患者生存的影响需要进一步的研究，目前暂不予推荐。 编译：
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-13 17:11
医学,生命科学网